Proceeds of $10.1 Million Raised
SBC Medical Group Holdings Incorporated, a prominent Management Service Organisation, has completed a secondary public offering of 3.1 million shares of common stock. This announcement was made on April 21st.
Offered at a public price of $3.25 per share, the transaction generated approximately $10.1 million in proceeds for the selling stockholder, Dr. Yoshiyuki Aikawa. The company itself did not sell any shares in this offering, and all proceeds were directed to Dr. Aikawa.
Maxim Group LLC acted as the sole book-running manager, while Roth Capital Partners served as the co-manager for the transaction.
Offering Details
The shares were sold under SBC Medical’s effective shelf registration statement on Form S-3, filed with the U.S. Securities and Exchange Commission (SEC). Conducted exclusively through a prospectus supplement and the accompanying prospectus, the offering adhered to SEC regulations. A final prospectus supplement detailing the offering terms has been filed with the SEC.
Copies of the preliminary and final prospectus supplements are available on the SEC’s website. Interested parties can also contact Maxim Group LLC for more information.
SBC Medical Group Holdings operates a diverse range of franchise businesses in various medical fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The company is actively expanding its global presence, particularly in the United States and Asia, through direct operations and medical tourism initiatives.
Listed on Nasdaq since September 2024, SBC Medical was also included in the Russell 3000® Index in June 2025, a significant benchmark of the U.S. equity market.
Guided by its mission to contribute to global well-being through medical innovation, SBC Medical continues to provide safe, high-quality medical services. The Company’s efforts include managing a diverse portfolio of clinic brands and focusing on medical developments that enhance patient care.
Dr. Yoshiyuki Aikawa, the selling stockholder, is instrumental in the company’s advancement. His decision to offer 3.1 million shares highlights his confidence in SBC Medical’s growth trajectory. The transaction was structured to ensure compliance with all legal requirements in applicable jurisdictions. SBC Medical’s commitment to excellence is evident as they maintain high standards in every aspect of their operations.
The offering was not an invitation to sell or buy securities in any region where such actions are unlawful without proper registration. The Company emphasises that all transactions are conducted with full adherence to state and federal securities laws.
Last updated: 22 April 2026, 10:19 am
